Chen Xiang, Yang Changcheng, Wang Wei, He Xionghui, Sun Hening, Lyu Wenzhi, Zou Kejian, Fang Shuo, Dai Zhijun, Dong Huaying
Department of General Surgery, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, China.
Department of Medical Oncology, The First Affiliated Hospital of Hainan Medical University, Haikou, China.
Front Genet. 2023 Feb 24;14:1025163. doi: 10.3389/fgene.2023.1025163. eCollection 2023.
Breast cancer (BRCA) is a life-threatening malignancy in women with an unsatisfactory prognosis. The purpose of this study was to explore the prognostic biomarkers and a risk signature based on ferroptosis-related RNA-binding proteins (FR-RBPs). FR-RBPs were identified using Spearman correlation analysis. Differentially expressed genes (DEGs) were identified by the "limma" R package. The univariate Cox and multivariate Cox analyses were executed to determine the prognostic genes. The risk signature was constructed and verified with the training set, testing set, and validation set. Mutation analysis, immune checkpoint expression analysis in high- and low-risk groups, and correlation between risk signature and chemotherapeutic agents were conducted using the "maftools" package, "ggplot2" package, and the CellMiner database respectively. The Human Protein Atlas (HPA) database was employed to confirm protein expression trends of prognostic genes in BRCA and normal tissues. The expression of prognostic genes in cell lines was verified by Real-time quantitative polymerase chain reaction (RT-qPCR). Kaplan-meier (KM) plotter database analysis was applied to predict the correlation between the expression levels of signature genes and survival statuses. Five prognostic genes (GSPT2, RNASE1, TIPARP, TSEN54, and SAMD4A) to construct an FR-RBPs-related risk signature were identified and the risk signature was validated by the International Cancer Genome Consortium (ICGC) cohort. Univariate and multivariate Cox regression analysis demonstrated the risk score was a robust independent prognostic factor in overall survival prediction. The Tumor Mutational Burden (TMB) analysis implied that the high- and low-risk groups responded differently to immunotherapy. Drug sensitivity analysis suggested that the risk signature may serve as a chemosensitivity predictor. The results of GSEA suggested that five prognostic genes might be related to DNA replication and the immune-related pathways. RT-qPCR results demonstrated that the expression trends of prognostic genes in cell lines were consistent with the results from public databases. KM plotter database analysis suggested that high expression levels of GSPT2, RNASE1, and SAMD4A contributed to poor prognoses. In conclusion, this study identified the FR-RBPs-related prognostic genes and developed an FR-RBPs-related risk signature for the prognosis of BRCA, which will be of great significance in developing new therapeutic targets and prognostic molecular biomarkers for BRCA.
乳腺癌(BRCA)是一种威胁生命的恶性肿瘤,预后不理想。本研究的目的是探索基于铁死亡相关RNA结合蛋白(FR-RBPs)的预后生物标志物和风险特征。使用Spearman相关性分析鉴定FR-RBPs。通过“limma”R包鉴定差异表达基因(DEGs)。进行单变量Cox和多变量Cox分析以确定预后基因。构建风险特征并用训练集、测试集和验证集进行验证。分别使用“maftools”包、“ggplot2”包和CellMiner数据库进行突变分析、高风险和低风险组的免疫检查点表达分析以及风险特征与化疗药物之间的相关性分析。利用人类蛋白质图谱(HPA)数据库确认BRCA和正常组织中预后基因的蛋白质表达趋势。通过实时定量聚合酶链反应(RT-qPCR)验证细胞系中预后基因的表达。应用Kaplan-meier(KM)绘图仪数据库分析来预测特征基因表达水平与生存状态之间的相关性。鉴定出五个用于构建FR-RBPs相关风险特征的预后基因(GSPT2、RNASE1、TIPARP、TSEN54和SAMD4A),并且该风险特征通过国际癌症基因组联盟(ICGC)队列得到验证。单变量和多变量Cox回归分析表明,风险评分是总生存预测中一个可靠的独立预后因素。肿瘤突变负荷(TMB)分析表明,高风险和低风险组对免疫治疗的反应不同。药物敏感性分析表明,风险特征可作为化疗敏感性预测指标。基因集富集分析(GSEA)结果表明,五个预后基因可能与DNA复制和免疫相关途径有关。RT-qPCR结果表明,细胞系中预后基因的表达趋势与公共数据库的结果一致。KM绘图仪数据库分析表明,GSPT2、RNASE1和SAMD4A的高表达导致预后不良。总之,本研究鉴定出FR-RBPs相关的预后基因,并开发了一种用于BRCA预后的FR-RBPs相关风险特征,这对于开发BRCA的新治疗靶点和预后分子生物标志物具有重要意义。